Medical Device

Designed specifically for small vessels, Medtronic (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Resolute Onyx(TM) 2.0 mm Drug-Eluting Stent (DES) – the smallest sized DES on the market. The new stent is intended to help interventional cardiologists treat patients with coronary artery disease (CAD) who …

Designed specifically for small vessels, Medtronic (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Resolute Onyx(TM) 2.0 mm Drug-Eluting Stent (DES) – the smallest sized DES on the market. The new stent is intended to help interventional cardiologists treat patients with coronary artery disease (CAD) who have small vessels often untreatable with larger stent technologies during percutaneous coronary intervention (PCI).

As quoted in the press release:

“Patients with lesions in small vessels or complex vasculatures can present unique challenges for physicians during PCI procedures,” said Matthew J. Price, M.D., interventional cardiologist at Scripps Clinic in La Jolla, Calif., and national principal investigator of the RESOLUTE ONYX 2.0 mm Clinical Study, which supported the recent FDA approval. “The Resolute Onyx 2.0 mm DES is an extremely deliverable stent that, when needed, can be post-dilated to 3.25 mm to treat lesions in difficult-to-reach areas of the heart.”

Click here to read the full press release.

MARKETS

Markets
TSX18834.16-194.70
TSXV615.94-7.29
DOW30967.82-129.44
S&P 5003831.39+6.06
NASD11322.24+194.39
ASX6612.60+72.70

COMMODITIES

Commodities
Gold1765.72-43.38
Silver19.23-0.75
Copper3.43-0.17
Palladium1938.00+0.50
Platinum869.00-15.01
Oil99.62-8.81
Heating Oil3.58-0.36
Natural Gas5.49-0.24

DOWNLOAD FREE REPORTS

×